Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Escherichia coli adhesion to uroepithelial cells" refers not to a single molecular target but rather a **pathogenic process** mediated primarily by specific surface proteins and organelles expressed by uropathogenic Escherichia coli (UPEC). The most studied and therapeutically relevant molecular target within this process is the **type 1 fimbrial adhesin FimH**, which is located at the tip of type 1 pili. These adhesive organelles—including type 1, P, and S pili as well as Dr family adhesins—enable E. coli to attach firmly to receptors such as integrins and uroplakins on the surface of bladder epithelial cells[1][3][4]. This attachment is essential for colonization, invasion into host tissues, biofilm formation within intracellular bacterial communities (IBCs), and evasion from immune responses[2][3]. Drugs like dictamnine have been shown experimentally to inhibit this adhesive interaction in vitro[4]. **Note:** There is something incorrect about using "Escherichia coli adhesion to uroepithelial cells" as a canonical therapeutic target name. It describes a biological process rather than a discrete molecule or receptor. The actual druggable targets are specific E. coli proteins such as FimH or other pilus-associated adhesins; these should be used for structured data purposes instead. > “Adhesive organelles including type 1...pili along with Dr adhesins promote both bacterial attachment...within the urinary tract.” [1] > “One of the main strategies...is targeting bacterial adhesion by inhibiting...FimH.” [3] > “UPEC adhere to urothelial cells through type 1 fimbriae which bind...to integrin and uroplakin receptors.” [4] If you need structured information for an actual molecular target involved in this process—such as "Escherichia coli type 1 fimbrial adhesin (FimH)"—please specify so that more precise data can be provided.
Inhibition of bacterial adhesion to uroepithelial cells by blocking FimH or other fimbrial/adhesin interactions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli type 1 fimbrial adhesin (FimH) (FimH).